What links CRSwNP, asthma, and other comorbidities? In this episode, our experts unpack the unified airways concept and why it’s key to understanding Type 2 inflammation and optimizing patient care. Our experts discuss integrated care approaches and what they mean for clinical practice.

In this episode of Polyp Gossip, we explore the importance of a multidisciplinary approach in managing Chronic Rhinosinusitis with Nasal Polyps (CRSwNP). Join leading experts from rhinology and pulmonology as they discuss how collaboration across specialties can improve patient outcomes and optimize care pathways.

Fabry disease is an X-linked lysosomal storage disease due to a defect in the gene encoding the lysosomal enzyme alpha-galactosidase A (α-Gal A), causing progressive cellular accumulation of the substrate globotriaosylceramide (GL-3) and globo-triaosylsphingosine (lyso-GL-3).

Think Fabry, think timely testing first.

Think Fabry, think regular profile-based assessments.

Cardiovascular disease is the leading cause of death in Fabry disease patients.¹ Undiagnosed and untreated Fabry disease leads to progressive, irreversible, life-threatening heart injury.^2,3

Think Fabry, think renal involvement that may present early in life and could go undetected.

Think Fabry, think screening at-risk family members.¹

Think Fabry, think early treatment to help slow or prevent life-threatening disease progression.^1,2

A post-hoc pooled analysis to evaluate efficacy and safety of insulin glargine 300 U/mL in insulin-naïve people with type 2 diabetes with/ without prior use of glucagon-like peptide-1 receptor agonist therapy.¹

A podcast series designed by cardiologists, for cardiologists and other healthcare professionals.

Toujeo is a 2nd generation, long-acting insulin analog containing insulin glargine 300 units/mL. Toujeo® is available in two prefilled pens. See how Toujeo® is administrated In six simple steps and watch instructional video.